Skip to main content Accessibility help
×
Hostname: page-component-77f85d65b8-8v9h9 Total loading time: 0 Render date: 2026-04-16T01:17:55.834Z Has data issue: false hasContentIssue false

33 - Hematologic supportive care

from Part IV - Complications and supportive care

Published online by Cambridge University Press:  01 July 2010

By
Fariba Navid  and
Victor M. Santana
Edited by
Ching-Hon Pui
Fariba Navid
Affiliation:
Assistant Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
Victor M. Santana
Affiliation:
Member and Director, Solid Tumor Division, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
Ching-Hon Pui
Affiliation:
St. Jude Children's Research Hospital, Memphis
Get access

Summary

Introduction

The great strides that have been made in curing children of acute leukemia can be attributed in part to improvements in supportive care during periods of morbidity due to therapeutic interventions. Such care is a major component of the total patient management strategy and includes nutritional support, prophylaxis against life-threatening infections, empiric use of antibiotics during periods of neutropenia, blood component support, adequate venous access, and, most recently, the use of hematopoietic growth factors to ameliorate hematologic complications. In this chapter, we review the current status of blood component support, intravenous catheter placement, and supportive therapy with granulocyte colony-stimulating factor and other cytokines. Although the focus is on experience with childhood leukemias, some examples are drawn from experience with solid tumor patients, particularly in situations where limited data are available from leukemia studies.

Blood component support

Since 1828, when Blundell initiated the use of blood transfusion to counteract postpartum hemorrhages, the demand for blood component products in the United States has increased exponentially. Each year, approximately 12 million units of blood are transfused in this country, with surgery, motor vehicle accidents, and complications of cancer accounting for the majority of this usage. Cancer patients receive blood component support because of deficient hemoglobin levels and platelet counts caused by the suppression of blood cell progenitors or by bone marrow aplasia due to tumor cell infiltration.

The use of red cell and plasma products has remained constant over the last decade, while platelet usage has steadily increased.

Information

Type
Chapter
Information
Childhood Leukemias , pp. 829 - 849
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Blundell, J.Successful case of transfusion. Lancet, 1828; 1: 431.Google Scholar
Skillings, J. R., Sridhar, F. G., Wong, C., & Paddock, L.The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol, 1993; 16: 22–5.CrossRefGoogle ScholarPubMed
Simone, J. V.Use of fresh blood components during intensive combination therapy of childhood leukemia. Cancer, 1971; 28: 562–5.3.0.CO;2-P>CrossRefGoogle ScholarPubMed
Warkentin, P. Transfusion therapy for the pediatric oncology patient. In , D. Kasprisin & , N. Luban, eds., Pediatric Transfusion Medicine, vol. 2. (Boca Raton, FL: CRC Press, 1987).Google Scholar
Gaydas, L., Freireich, E., & Mantel, N.The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med, 1963; 266: 905–9.CrossRefGoogle Scholar
Schiffer, C. A., Anderson, K. C., Bennett, C. L., et al.Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 2001; 19: 1519–38.CrossRefGoogle ScholarPubMed
Gmur, J., Burger, J., Schanz, U., Fehr, J., & Schaffner, A.Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet, 1991; 338: 1223–6.CrossRefGoogle ScholarPubMed
Heckman, K. D., Weiner, G. J., Davis, C. S., et al.Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol, 1997; 15: 1143–9.CrossRefGoogle ScholarPubMed
Wandt, H., Frank, M., Ehninger, G., et al.Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood, 1998; 91: 3601–6.Google ScholarPubMed
Rebulla, P., Finazzi, G., Marangoni, F., et al.The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med, 1997; 337: 1870–5.CrossRefGoogle ScholarPubMed
Friedmann, A. M., Sengul, H., Lehmann, H., Schwartz, C., & Goodman, S.Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients ? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev, 2002; 16: 34–45.CrossRefGoogle ScholarPubMed
Howard, S. C., Gajjar, A., Ribeiro, R. C., et al.Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA, 2000; 284: 2222–4.CrossRefGoogle ScholarPubMed
Howard, S. C., Gajjar, A. J., Cheng, C., et al.Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA, 2002; 288: 2001–7.CrossRefGoogle ScholarPubMed
Gajjar, A., Harrison, P. L., Sandlund, J. T., et al.Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000; 96: 3381–4.Google ScholarPubMed
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med, 1997; 337: 1861–9.
O'Connell, B., Lee, E. J., & Schiffer, C. A.The value of 10-minute posttransfusion platelet counts. Transfusion, 1988; 28: 66–7.CrossRefGoogle ScholarPubMed
Bishop, J. F., McGrath, K., Wolf, M. M., et al.Clinical factors influencing the efficacy of pooled platelet transfusions. Blood, 1988; 71: 383–7.Google ScholarPubMed
Engelfriet, C. P., Reesink, H. W., Aster, R. H., et al.Management of alloimmunized, refractory patients in need of platelet transfusions. Vox Sang, 1997; 73: 191–8.CrossRefGoogle ScholarPubMed
Rebulla, P.Refractoriness to platelet transfusion. Curr Opin Hematol, 2002; 9: 516–20.CrossRefGoogle ScholarPubMed
Nagasawa, T., Kim, B. K., & Baldini, M. G.Temporary suppression of circulating antiplatelet alloantibodies by the massive infusion of fresh, stored, or lyophilized platelets. Transfusion, 1978; 18: 429–35.CrossRefGoogle ScholarPubMed
Kobrinsky, N. L. & Tulloch, H.Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). J Pediatr, 1988; 112: 993–6.CrossRefGoogle Scholar
Kickler, T., Braine, H. G., Piantadosi, S., et al.A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood, 1990; 75: 313–16.Google ScholarPubMed
Zeigler, Z. R., Shadduck, R. K., Rosenfeld, C. S., et al.High-dose intravenous gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusion. Blood, 1987; 70: 1433–6.Google ScholarPubMed
Consensus conference. Fresh-frozen plasma. Indications and risks. JAMA, 1985; 253: 551–3.CrossRef
National Blood Resource Education Program. Indications for the Use of Red Blood Cells, Platelets, and Fresh Frozen Plasma. NIH Publication 89–2974. (Rockville, MD: National Institutes of Health, 1989).
Dale, D. C.The discovery, development and clinical applications of granulocyte colony-stimulating factor. Trans Am Clin Climatol Assoc, 1998; 109: 27–36, 36–8.Google ScholarPubMed
Cavallaro, A. M., Lilleby, K., Majolino, I., et al.Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant, 2000; 25: 85–9.CrossRefGoogle ScholarPubMed
Volk, E. E., Domen, R. E., & Smith, M. L.An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Arch Pathol Lab Med, 1999; 123: 508–13.Google ScholarPubMed
Anderlini, P., Korbling, M., Dale, D., et al.Allogeneic blood stem cell transplantation: considerations for donors. Blood, 1997; 90: 903–8.Google ScholarPubMed
Dodd, R.Infectious complications of blood transfusion. Hematol Oncol Ann, 1994; 2: 280–7.Google Scholar
Bowden, R. A., Slichter, S. J., Sayers, M., et al.A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood, 1995; 86: 3598–603.Google ScholarPubMed
American Association of Blood Banks. Transfusion transmitted diseases. In , M. Brecher, ed., Technical Manual, 50th, Anniversary AABB Edition, 1953–2003, 14th edn. (Bethesda, MD: American Association of Blood Banks, 2002).Google Scholar
Grant, P. R. & Busch, M. P.Nucleic acid amplification technology methods used in blood donor screening. Transfus Med, 2002; 12: 229–42.CrossRefGoogle ScholarPubMed
Williams, A. E. & Sullivan, M. T.Transfusion-transmitted retrovirus infection. Hematol Oncol Clin North Am, 1995; 9: 115–36.CrossRefGoogle ScholarPubMed
Reading, F. C. & Brecher, M. E.Transfusion-related bacterial sepsis. Curr Opin Hematol, 2001; 8: 380–6.CrossRefGoogle ScholarPubMed
Goodnough, L. T., Brecher, M. E., Kanter, M. H., & AuBuchon, J. P.Transfusion medicine. First of two parts – blood transfusion. N Engl J Med, 1999; 340: 438–47.CrossRefGoogle ScholarPubMed
Kuehnert, M. J., Roth, V. R., Haley, N. R., et al.Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion, 2001; 41: 1493–9.CrossRefGoogle ScholarPubMed
Workshop on Safety and Efficacy of Methods in Reducing Pathogens in Cellular Products Used in Transfusion, Bethesda, Maryland, August 7, 2002. (Rockville, MD: FDA, Center for Biologics Evaluation and Research, 2002).
Petersen, L. R., Roehrig, J. T., & Hughes, J. M.West Nile virus encephalitis. N Engl J Med, 2002; 347: 1225–6.CrossRefGoogle ScholarPubMed
Pealer, L. N., Marfin, A. A., Petersen, L. R., et al.Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med, 2003; 349: 1236–45.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Update: West Nile virus screening of blood donations and transfusion-associated transmission–United States, 2003. MMWR, 2004; 53: 281–4.
Brown, P., Will, R. G., Bradley, R., Asher, D. M., & Detwiler, L.Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis, 2001; 7: 6–16.CrossRefGoogle ScholarPubMed
Hunter, N., Foster, J., Chong, A., et al.Transmission of prion diseases by blood transfusion. J Gen Virol, 2002; 83: 2897–905.CrossRefGoogle ScholarPubMed
Chamberland, M. E., Alter, H. J., Busch, M. P., Nemo, G.,& Ricketts, M.Emerging infectious disease issues in blood safety. Emerg Infect Dis, 2001; 7(Suppl.): 552–3.CrossRefGoogle ScholarPubMed
Stowell, C. P.Hemoglobin-based oxygen carriers. Curr Opin Hematol, 2002; 9: 537–43.CrossRefGoogle ScholarPubMed
Broviac, J. W., Cole, J. J., & Scribner, B. B.A silicone rubber atrial catheter for prolonged parenteral alimentation. Surg Gynecol Obstet, 1973; 136: 602–6.Google ScholarPubMed
Hickman, R. O., Buckner, C. D., Clift, R. A., et al.A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet, 1979; 148: 871–5.Google ScholarPubMed
Lokich, J. J., Bothe, A Jr., Benotti, P., & Moore, C.Complications and management of implanted venous access catheters. J Clin Oncol, 1985; 3: 710–7.CrossRefGoogle ScholarPubMed
Choi, M., Massicotte, M. P., Marzinotto, V., et al.The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr, 2001; 139: 152–6.CrossRefGoogle ScholarPubMed
Jacobs, B. R., Haygood, M., & Hingl, J.Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr, 2001; 139: 593–6.CrossRefGoogle ScholarPubMed
Chesler, L. & Feusner, J. H.Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. J Pediatr Hematol Oncol, 2002; 24: 653–6.CrossRefGoogle ScholarPubMed
Shen, V., Li, X., Murdock, M., et al.Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol, 2003; 25: 38–45.CrossRefGoogle ScholarPubMed
Duffy, L. F., Kerzner, B., Gebus, V., & Dice, J.Treatment of central venous catheter occlusions with hydrochloric acid. J Pediatr, 1989; 114: 1002–4.CrossRefGoogle ScholarPubMed
Wurzel, C. L., Halom, K., Feldman, J. G., & Rubin, L. G.Infection rates of Broviac-Hickman catheters and implantable venous devices. Am J Dis Child, 1988; 142: 536–40.Google ScholarPubMed
Clarke, D. E. & Raffin, T. A.Infectious complications of indwelling long-term central venous catheters. Chest, 1990; 97: 966–72.CrossRefGoogle ScholarPubMed
Gaillard, J. L., Merlino, R., Pajot, N., et al.Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci. J Parenter Enteral Nutr, 1990; 14: 593–7.CrossRefGoogle ScholarPubMed
Maki, D. G., Cobb, L., Garman, J. K., et al.An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am J Med, 1988; 85: 307–14.CrossRefGoogle ScholarPubMed
Rudolph, R. & Larson, D. L.Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol, 1987; 5: 1116–26.CrossRefGoogle ScholarPubMed
Lehrnbecher, T. & Welte, K.Haematopoietic growth factors in children with neutropenia. Br J Haematol, 2002; 116: 28–56.CrossRefGoogle ScholarPubMed
Levine, J. E. & Boxer, L. A.Clinical applications of hematopoietic growth factors in pediatric oncology. Curr Opin Hematol, 2002; 9: 222–7.CrossRefGoogle ScholarPubMed
Lord, B. I., Bronchud, M. H., Owens, S., et al.The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A, 1989; 86: 9499–503.CrossRefGoogle ScholarPubMed
Morstyn, G., Campbell, L., Souza, L. M., et al.Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet, 1988; 1: 667–72.CrossRefGoogle ScholarPubMed
Pui, C. H., Boyett, J. M., Hughes, W. T., et al.Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med, 1997; 336: 1781–7.CrossRefGoogle ScholarPubMed
Welte, K., Reiter, A., Mempel, K., et al.A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. Blood, 1996; 87: 3143–50.Google ScholarPubMed
Michel, G., Landman-Parker, J., Auclerc, M. F., et al.Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol, 2000; 18: 1517–24.CrossRefGoogle ScholarPubMed
Laver, J., Amylon, M., Desai, S., et al.Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol, 1998; 16: 522–6.CrossRefGoogle Scholar
Negrin, R. S., Haeuber, D. H., Nagler, A., et al.Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I–II trial. Ann Intern Med, 1989; 110: 976–84.CrossRefGoogle ScholarPubMed
Cannistra, S. A., DiCarlo, J., Groshek, P., et al.Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia, 1991; 5: 230–8.Google ScholarPubMed
Relling, M. V., Boyett, J. M., Blanco, J. G., et al.Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood, 2003; 101: 3862–7.CrossRefGoogle ScholarPubMed
Stute, N., Santana, V. M., Rodman, J. H., et al.Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood, 1992; 79: 2849–54.Google ScholarPubMed
Meropol, N. J., Miller, L. L., Korn, E. L., et al.Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst, 1992; 84: 1201–3.CrossRefGoogle ScholarPubMed
Rowinsky, E., Satorius, S., & Grochow, L.Phase I and pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony-stimulating factor (G-CSF): toxicological differences between concurrent and post-treatment G-CSF administration. Proc Am Soc Clin Oncol, 1992; 11: 116.Google Scholar
Rahiala, J., Perkkio, M., & Riikonen, P.Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer. Med Pediatr Oncol, 1999; 32: 326–30.3.0.CO;2-B>CrossRefGoogle Scholar
Soda, H., Oka, M., Fukuda, M., et al.Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol, 1996; 38: 9–12.CrossRefGoogle ScholarPubMed
Hofmann, W. K., Seipelt, G., Langenhan, S., et al.Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol, 2002; 81: 570–4.Google ScholarPubMed
Lefrere, F., Audat, F., Hermine, O., et al.The timing of granulocyte-colony-stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: a retrospective study of 65 cases. Transfusion, 1999; 39: 561–4.CrossRefGoogle Scholar
Wright, D. G., Meierovics, A. I., & Foxley, J. M.Assessing the delivery of neutrophils to tissues in neutropenia. Blood, 1986; 67: 1023–30.Google ScholarPubMed
American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol, 1994; 12: 2471–508.CrossRef
American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol, 1996; 14: 1957–60.CrossRef
Ozer, H., Armitage, J. O., Bennett, C. L., et al.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol, 2000; 18: 3558–85.CrossRefGoogle Scholar
Schaison, G., Eden, O. B., Henze, G., et al.Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr, 1998; 157: 955–66.CrossRefGoogle ScholarPubMed
Morstyn, G., Foote, M. A., Walker, T., & Molineux, G.Filgrastim (r-metHuG-CSF) in the 21st century: SD/01. Acta Haematol, 2001; 105: 151–5.CrossRefGoogle ScholarPubMed
Vose, J. M., Crump, M., Lazarus, H., et al.Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol, 2003; 21: 514–19.CrossRefGoogle ScholarPubMed
Holmes, F. A., O'Shaughnessy, J. A., Vukelja, S., et al.Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol, 2002; 20: 727–31.CrossRefGoogle ScholarPubMed
Green, M. D., Koelbl, H., Baselga, J., et al.A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol, 2003; 14: 29–35.CrossRefGoogle ScholarPubMed
Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D.Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol, 1998; 16: 3412–25.CrossRefGoogle ScholarPubMed
Abels, R.Erythropoietin for anaemia in cancer patients. Eur J Cancer, 1993; 29A(Suppl. 2): S2–8.CrossRefGoogle ScholarPubMed
Glaspy, J., Bukowski, R., Steinberg, D., et al.Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol, 1997; 15: 1218–34.CrossRefGoogle ScholarPubMed
Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., & Rapoport, B.Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 2001; 19: 2865–74.CrossRefGoogle ScholarPubMed
Corazza, F., Beguin, Y., Bergmann, P., et al.Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood, 1998; 92: 1793–8.Google Scholar
Kuter, D. J. & Begley, C. G.Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood, 2002; 100: 3457–69.CrossRefGoogle ScholarPubMed
Glynn, S. A., Kleinman, S. H., Schreiber, G. B., et al.Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA, 2000; 284: 229–35.CrossRefGoogle Scholar
Wagner, L. M., Billups, C. A., Furman, W. L., Rao, B. N., & Santana, V. M.Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol, 2004; 22: 1886–93.CrossRefGoogle Scholar
Porter, J. C., Leahey, A., Polise, K., Bunin, G., & Manno, C. S.Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr, 1996; 129: 656–60.CrossRefGoogle ScholarPubMed
Bolonaki, I., Stiakaki, E., Lydaki, E., et al.Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol, 1996; 13: 111–21.CrossRefGoogle ScholarPubMed
Varan, A., Buyukpamukcu, M., Kutluk, T., & Akyuz, C.Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics, 1999; 103: E16.CrossRefGoogle ScholarPubMed
Kronberger, M., Fischmeister, G., Poetschger, U., Gadner, H., & Zoubek, A.Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: a case-control study. Pediatr Hematol Oncol, 2002; 19: 95–105.CrossRefGoogle ScholarPubMed
Leon, P., Jimenez, M., Barona, P., & Sierrasesumaga, L.Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol, 1998; 30: 110–6.3.0.CO;2-L>CrossRefGoogle ScholarPubMed

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this chapter is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Hematologic supportive care
    • By Fariba Navid, Assistant Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA, Victor M. Santana, Member and Director, Solid Tumor Division, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
  • Edited by Ching-Hon Pui
  • Book: Childhood Leukemias
  • Online publication: 01 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511471001.034
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Hematologic supportive care
    • By Fariba Navid, Assistant Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA, Victor M. Santana, Member and Director, Solid Tumor Division, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
  • Edited by Ching-Hon Pui
  • Book: Childhood Leukemias
  • Online publication: 01 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511471001.034
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Hematologic supportive care
    • By Fariba Navid, Assistant Member, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA, Victor M. Santana, Member and Director, Solid Tumor Division, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
  • Edited by Ching-Hon Pui
  • Book: Childhood Leukemias
  • Online publication: 01 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511471001.034
Available formats
×